Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Quantitative mobility metrics from a wearable sensor predict incident parkinsonism in older adults.

von Coelln R, Dawe RJ, Leurgans SE, Curran TA, Truty T, Yu L, Barnes LL, Shulman JM, Shulman LM, Bennett DA, Hausdorff JM, Buchman AS.

Parkinsonism Relat Disord. 2019 Aug;65:190-196. doi: 10.1016/j.parkreldis.2019.06.012. Epub 2019 Jun 22.

PMID:
31272924
2.

Tackling the imposter phenomenon to advance women in neurology.

Armstrong MJ, Shulman LM.

Neurol Clin Pract. 2019 Apr;9(2):155-159. doi: 10.1212/CPJ.0000000000000607.

PMID:
31041131
3.

Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms.

Blauwendraat C, Heilbron K, Vallerga CL, Bandres-Ciga S, von Coelln R, Pihlstrøm L, Simón-Sánchez J, Schulte C, Sharma M, Krohn L, Siitonen A, Iwaki H, Leonard H, Noyce AJ, Tan M, Gibbs JR, Hernandez DG, Scholz SW, Jankovic J, Shulman LM, Lesage S, Corvol JC, Brice A, van Hilten JJ, Marinus J; 23andMe Research Team, Eerola-Rautio J, Tienari P, Majamaa K, Toft M, Grosset DG, Gasser T, Heutink P, Shulman JM, Wood N, Hardy J, Morris HR, Hinds DA, Gratten J, Visscher PM, Gan-Or Z, Nalls MA, Singleton AB; International Parkinson's Disease Genomics Consortium (IPDGC).

Mov Disord. 2019 Jun;34(6):866-875. doi: 10.1002/mds.27659. Epub 2019 Apr 7.

PMID:
30957308
4.

First report of a persistent oropharyngeal infection of type 2 vaccine-derived poliovirus (iVDPV2) in a primary immune deficient (PID) patient after eradication of wild type 2 poliovirus.

Weil M, Rahav G, Somech R, Stauber T, Alfandari J, Weiss L, Silberstein I, Indenbaum V, Or IB, Mendelson E, Sofer D, Shulman LM.

Int J Infect Dis. 2019 Jun;83:40-43. doi: 10.1016/j.ijid.2019.03.037. Epub 2019 Apr 3.

5.

No evidence of an increase in the incidence of norovirus gastroenteritis hospitalizations in young children after the introduction of universal rotavirus immunization in Israel.

Muhsen K, Kassem E, Rubenstein U, Goren S, Ephros M, Shulman LM, Cohen D.

Hum Vaccin Immunother. 2019;15(6):1284-1293. doi: 10.1080/21645515.2019.1599522. Epub 2019 May 3.

PMID:
30945960
6.

Comparative study of PROMIS self-efficacy for managing chronic conditions across chronic neurologic disorders.

Shulman LM, Velozo C, Romero S, Gruber-Baldini AL.

Qual Life Res. 2019 Jul;28(7):1893-1901. doi: 10.1007/s11136-019-02164-2. Epub 2019 Mar 26.

PMID:
30915674
7.

Multidimensionality of the PROMIS self-efficacy measure for managing chronic conditions.

Lee MJ, Romero S, Velozo CA, Gruber-Baldini AL, Shulman LM.

Qual Life Res. 2019 Jun;28(6):1595-1603. doi: 10.1007/s11136-019-02116-w. Epub 2019 Feb 26.

PMID:
30806873
8.

Epidemiology of the silent polio outbreak in Rahat, Israel, based on modeling of environmental surveillance data.

Brouwer AF, Eisenberg JNS, Pomeroy CD, Shulman LM, Hindiyeh M, Manor Y, Grotto I, Koopman JS, Eisenberg MC.

Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10625-E10633. doi: 10.1073/pnas.1808798115. Epub 2018 Oct 18.

9.

A novel magnetic beads-based method for polioviral concentration from environmental samples.

Perepliotchikov Y, Benhar I, Manor Y, Wilton T, Majumdar M, Martin J, Mendelson E, Shulman LM.

J Virol Methods. 2018 Oct;260:62-69. doi: 10.1016/j.jviromet.2018.07.005. Epub 2018 Jul 9.

PMID:
30003926
10.

Co-appearance of OPV and BCG vaccine-derived complications in two infants with severe combined immunodeficiency.

Heiman S, Weil M, Shulman LM, Simon AJ, Lev A, Somech R, Stauber T.

Immunol Res. 2018 Jun;66(3):437-443. doi: 10.1007/s12026-018-9007-6.

PMID:
29804197
11.

Parkinson's Disease: Patients' Knowledge, Attitudes, and Interest in Genetic Counseling.

Maloney KA, Alaeddin DS, von Coelln R, Dixon S, Shulman LM, Schrader K, Guan Y.

J Genet Couns. 2018 Sep;27(5):1200-1209. doi: 10.1007/s10897-018-0239-3. Epub 2018 Mar 2.

PMID:
29500627
12.

Utilization of rehabilitation therapy services in Parkinson disease in the United States.

Fullard ME, Thibault DP, Hill A, Fox J, Bhatti DE, Burack MA, Dahodwala N, Haberfeld E, Kern DS, Klepitskava OS, Urrea-Mendoza E, Myers P, Nutt J, Rafferty MR, Schwalb JM, Shulman LM, Willis AW; Parkinson Study Group Healthcare Outcomes and Disparities Working Group.

Neurology. 2017 Sep 12;89(11):1162-1169. doi: 10.1212/WNL.0000000000004355. Epub 2017 Aug 23.

13.

Viruses with Circular Single-Stranded DNA Genomes Are Everywhere!

Shulman LM, Davidson I.

Annu Rev Virol. 2017 Sep 29;4(1):159-180. doi: 10.1146/annurev-virology-101416-041953. Epub 2017 Jul 17. Review.

PMID:
28715975
14.

The factor structure of the Brief Symptom Inventory-18 (BSI-18) in Parkinson disease patients.

Abraham DS, Gruber-Baldini AL, Harrington D, Shulman LM.

J Psychosom Res. 2017 May;96:21-26. doi: 10.1016/j.jpsychores.2017.03.002. Epub 2017 Mar 6.

15.

Discordance Between Physician Assessment and Patient-Reported Depressive Symptoms in Parkinson Disease.

Lachner C, Armstrong MJ, Gruber-Baldini AL, Rezvani Z, Reich SG, Fishman PS, Salazar R, Shulman LM.

J Geriatr Psychiatry Neurol. 2017 Jul;30(4):191-195. doi: 10.1177/0891988717710335. Epub 2017 May 24.

PMID:
28535723
16.

Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study.

Muhsen K, Anis E, Rubinstein U, Kassem E, Goren S, Shulman LM, Ephros M, Cohen D.

Clin Microbiol Infect. 2018 Jan;24(1):53-59. doi: 10.1016/j.cmi.2017.04.018. Epub 2017 Apr 22.

17.

Validation of the PROMIS® measures of self-efficacy for managing chronic conditions.

Gruber-Baldini AL, Velozo C, Romero S, Shulman LM.

Qual Life Res. 2017 Jul;26(7):1915-1924. doi: 10.1007/s11136-017-1527-3. Epub 2017 Feb 26.

18.

Response shift - The experience of disease progression in Parkinson disease.

Yang J, Hanna-Pladdy B, Gruber-Baldini AL, Barr E, von Coelln R, Armstrong MJ, Reich SG, Shulman LM.

Parkinsonism Relat Disord. 2017 Mar;36:52-56. doi: 10.1016/j.parkreldis.2016.12.027. Epub 2016 Dec 29.

PMID:
28082015
19.

Prolonged excretion of type-2 poliovirus from a primary immune deficient patient during the transition to a type-2 poliovirus-free world, Israel, 2016.

Weil M, Shulman LM, Heiman S, Stauber T, Alfandari J, Weiss L, Silberstein I, Indenbaum V, Mendelson E, Sofer D.

Euro Surveill. 2016 Nov 24;21(47). pii: 30408. doi: 10.2807/1560-7917.ES.2016.21.47.30408.

20.

Clinical subtypes and genetic heterogeneity: of lumping and splitting in Parkinson disease.

von Coelln R, Shulman LM.

Curr Opin Neurol. 2016 Dec;29(6):727-734. Review.

PMID:
27749396
21.

Incidence of rotavirus gastroenteritis hospitalizations and genotypes, before and five years after introducing universal immunization in Israel.

Muhsen K, Kassem E, Rubenstein U, Goren S, Ephros M, Cohen D, Shulman LM.

Vaccine. 2016 Nov 21;34(48):5916-5922. doi: 10.1016/j.vaccine.2016.10.021. Epub 2016 Oct 19.

PMID:
27771186
22.

Asymmetric responsiveness of disability and health-related quality of life to improvement versus decline in Parkinson's disease.

Lamichhane D, Gruber-Baldini AL, Reich SG, Shulman LM.

Qual Life Res. 2016 Dec;25(12):3139-3145. Epub 2016 Jun 30.

PMID:
27363693
23.

Disability Rating Scales in Parkinson's Disease: Critique and Recommendations.

Shulman LM, Armstrong M, Ellis T, Gruber-Baldini A, Horak F, Nieuwboer A, Parashos S, Post B, Rogers M, Siderowf A, Goetz CG, Schrag A, Stebbins GT, Martinez-Martin P.

Mov Disord. 2016 Oct;31(10):1455-1465. doi: 10.1002/mds.26649. Review.

PMID:
27193358
24.

Are Patients with Psychogenic Movement Disorders More Likely to be Healthcare Workers?

Perry CG, Holmes KG, Gruber-Baldini AL, Anderson KE, Shulman LM, Weiner WJ, Reich SG.

Mov Disord Clin Pract. 2016 Apr 26;4(1):62-67. doi: 10.1002/mdc3.12351. eCollection 2017 Jan-Feb.

25.

Patient engagement and shared decision-making: What do they look like in neurology practice?

Armstrong MJ, Shulman LM, Vandigo J, Mullins CD.

Neurol Clin Pract. 2016 Apr;6(2):190-197.

26.

Assessment of the psychometrics of a PROMIS item bank: self-efficacy for managing daily activities.

Hong I, Velozo CA, Li CY, Romero S, Gruber-Baldini AL, Shulman LM.

Qual Life Res. 2016 Sep;25(9):2221-32. doi: 10.1007/s11136-016-1270-1. Epub 2016 Apr 5.

27.

Molecular Characterization of Polio from Environmental Samples: ISSP, The Israeli Sewage Surveillance Protocol.

Shulman LM, Manor Y, Hindiyeh M, Sofer D, Mendelson E.

Methods Mol Biol. 2016;1387:55-107. doi: 10.1007/978-1-4939-3292-4_5.

PMID:
26983731
28.

Sexual interactions with unfamiliar females reduce hippocampal neurogenesis among adult male rats.

Spritzer MD, Curtis MG, DeLoach JP, Maher J, Shulman LM.

Neuroscience. 2016 Mar 24;318:143-56. doi: 10.1016/j.neuroscience.2016.01.015. Epub 2016 Jan 12.

29.

How many OPV rounds are required to stop wild polio virus circulation in a developed country? Lessons from the Israeli experience.

Tasher D, Rahav G, Levine H, Sofer D, Linder N, Anis E, Shohat T, Manor Y, Kopel E, Shulman LM, Mendelson E, Shalit I, Somekh E.

Vaccine. 2016 Jan 12;34(3):299-301. doi: 10.1016/j.vaccine.2015.11.066. Epub 2015 Dec 9. No abstract available.

PMID:
26679402
30.

Mosquito Surveillance for 15 Years Reveals High Genetic Diversity Among West Nile Viruses in Israel.

Lustig Y, Hindiyeh M, Orshan L, Weiss L, Koren R, Katz-Likvornik S, Zadka H, Glatman-Freedman A, Mendelson E, Shulman LM.

J Infect Dis. 2016 Apr 1;213(7):1107-14. doi: 10.1093/infdis/jiv556. Epub 2015 Nov 23.

PMID:
26597260
31.

Coxsackievirus A6 Polymorphic Exanthem in Israeli Children.

Renert-Yuval Y, Marva E, Weil M, Shulman LM, Gencylmaz N, Sheffer S, Wolf DG, Molho-Pessach V.

Acta Derm Venereol. 2016 May;96(4):546-9. doi: 10.2340/00015555-2261.

32.

The Israeli public health response to wild poliovirus importation.

Kaliner E, Kopel E, Anis E, Mendelson E, Moran-Gilad J, Shulman LM, Singer SR, Manor Y, Somekh E, Rishpon S, Leventhal A, Rubin L, Tasher D, Honovich M, Moerman L, Shohat T, Bassal R, Sofer D, Gdalevich M, Lev B, Gamzu R, Grotto I.

Lancet Infect Dis. 2015 Oct;15(10):1236-1242. doi: 10.1016/S1473-3099(15)00064-X. Epub 2015 Jul 23.

PMID:
26213249
33.

A significant and consistent reduction in rotavirus gastroenteritis hospitalization of children under 5 years of age, following the introduction of universal rotavirus immunization in Israel.

Muhsen K, Rubenstein U, Kassem E, Goren S, Schachter Y, Kremer A, Shulman LM, Ephros M, Cohen D.

Hum Vaccin Immunother. 2015;11(10):2475-82. doi: 10.1080/21645515.2015.1056951.

34.

Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.

Augustine EF, Pérez A, Dhall R, Umeh CC, Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, Nance MA, Bainbridge J, Suchowersky O.

PLoS One. 2015 Jul 14;10(7):e0133002. doi: 10.1371/journal.pone.0133002. eCollection 2015.

35.

The urgent need to prevent type 1 autoimmune childhood diabetes.

Laron Z, Hampe CS, Shulman LM.

Pediatr Endocrinol Rev. 2015 Mar;12(3):266-82. Review.

PMID:
25962204
36.

Field study of fecal excretion as a decision support tool in response to silent reintroduction of wild-type poliovirus 1 into Israel.

Moran-Gilad J, Mendelson E, Burns CC, Bassal R, Gdalevich M, Sofer D, Oberste MS, Shulman LM, Kaliner E, Hindiyeh M, Mor O, Shahar L, Iber J, Yishay R, Manor J, Lev B, Gamzu R, Grotto I.

J Clin Virol. 2015 May;66:51-5. doi: 10.1016/j.jcv.2015.03.005. Epub 2015 Mar 10. Erratum in: J Clin Virol. 2015 Aug;251. Hindiye, Musa [corrected to Hindiyeh, Musa].

PMID:
25866337
37.

The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care.

Jensen RE, Rothrock NE, DeWitt EM, Spiegel B, Tucker CA, Crane HM, Forrest CB, Patrick DL, Fredericksen R, Shulman LM, Cella D, Crane PK.

Med Care. 2015 Feb;53(2):153-9. doi: 10.1097/MLR.0000000000000289. Review.

38.

Genetic analysis and characterization of wild poliovirus type 1 during sustained transmission in a population with >95% vaccine coverage, Israel 2013.

Shulman LM, Martin J, Sofer D, Burns CC, Manor Y, Hindiyeh M, Gavrilin E, Wilton T, Moran-Gilad J, Gamzo R, Mendelson E, Grotto I; GPI (Genotype–Phenotype Identification) Group; GPI Genotype-Phenotype Identification Group.

Clin Infect Dis. 2015 Apr 1;60(7):1057-64. doi: 10.1093/cid/ciu1136. Epub 2014 Dec 30.

PMID:
25550350
39.

Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.

Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, Pallansch MA, Thompson KM.

J Infect Dis. 2015 Jun 1;211(11):1800-12. doi: 10.1093/infdis/jiu674. Epub 2014 Dec 10.

PMID:
25505296
40.

Relationships between antiparkinson medication nonadherence, regimen modifications, and healthcare utilization and expenditures.

Wei YJ, Palumbo FB, Simoni-Wastila L, Shulman LM, Stuart B, Beardsley R, Brown C.

Parkinsonism Relat Disord. 2015 Jan;21(1):36-41. doi: 10.1016/j.parkreldis.2014.10.021. Epub 2014 Oct 31.

PMID:
25465748
41.

Laboratory challenges in response to silent introduction and sustained transmission of wild poliovirus type 1 in Israel during 2013.

Shulman LM, Mendelson E, Anis E, Bassal R, Gdalevich M, Hindiyeh M, Kaliner E, Kopel E, Manor Y, Moran-Gilad J, Ram D, Sofer D, Somekh E, Tasher D, Weil M, Gamzu R, Grotto I.

J Infect Dis. 2014 Nov 1;210 Suppl 1:S304-14. doi: 10.1093/infdis/jiu294. Review.

PMID:
25316849
42.

Which features of Parkinson's disease predict earlier exit from the workforce?

Armstrong MJ, Gruber-Baldini AL, Reich SG, Fishman PS, Lachner C, Shulman LM.

Parkinsonism Relat Disord. 2014 Nov;20(11):1257-9. doi: 10.1016/j.parkreldis.2014.08.005. Epub 2014 Aug 20.

PMID:
25179494
43.

Does spouse participation influence quality of life reporting in patients with Parkinson's disease?

Morrow CD, Smentkowski K, Schwartz S, Armstrong MJ, Gruber-Baldini AL, Anderson KE, Reich SG, Weiner WJ, Shulman LM.

Qual Life Res. 2015 Jan;24(1):245-9. doi: 10.1007/s11136-014-0744-2. Epub 2014 Jun 28.

PMID:
24972974
44.

Changes in the sexual behavior and testosterone levels of male rats in response to daily interactions with estrus females.

Shulman LM, Spritzer MD.

Physiol Behav. 2014 Jun 22;133:8-13. doi: 10.1016/j.physbeh.2014.05.001. Epub 2014 May 9.

45.

Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.

Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang GS, Ross GW, Tilley BC, Shulman LM; NET-PD Investigators.

JAMA Neurol. 2014 Jun;71(6):710-6. doi: 10.1001/jamaneurol.2014.391.

46.

Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a Medicare Part D population.

Wei YJ, Palumbo FB, Simoni-Wastila L, Shulman LM, Stuart B, Beardsley R, Brown CH.

Value Health. 2014 Mar;17(2):196-204. doi: 10.1016/j.jval.2013.12.003.

47.

Intensified environmental surveillance supporting the response to wild poliovirus type 1 silent circulation in Israel, 2013.

Manor Y, Shulman LM, Kaliner E, Hindiyeh M, Ram D, Sofer D, Moran-Gilad J, Lev B, Grotto I, Gamzu R, Mendelson E.

Euro Surveill. 2014 Feb 20;19(7):20708.

48.

Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013.

Shulman LM, Gavrilin E, Jorba J, Martin J, Burns CC, Manor Y, Moran-Gilad J, Sofer D, Hindiyeh MY, Gamzu R, Mendelson E, Grotto I; Genotype - Phenotype Identification (GPI) group.

Euro Surveill. 2014 Feb 20;19(7):20709.

49.

Development and validation of a real time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay for investigation of wild poliovirus type 1-South Asian (SOAS) strain reintroduced into Israel, 2013 to 2014.

Hindiyeh MY, Moran-Gilad J, Manor Y, Ram D, Shulman LM, Sofer D, Mendelson E.

Euro Surveill. 2014 Feb 20;19(7):20710. Erratum in: Euro Surveill. 2014;19(8):20717.

50.

Antibodies to islet cell autoantigens, rotaviruses and/or enteroviruses in cord blood and healthy mothers in relation to the 2010-2011 winter viral seasons in Israel: a pilot study.

Shulman LM, Hampe CS, Ben-Haroush A, Perepliotchikov Y, Vaziri-Sani F, Israel S, Miller K, Bin H, Kaplan B, Laron Z.

Diabet Med. 2014 Jun;31(6):681-5. doi: 10.1111/dme.12404. Epub 2014 Feb 25.

Supplemental Content

Loading ...
Support Center